Healthcare Providers and Services
Company Overview of The General Hospital Corporation
The General Hospital Corporation operates as a general hospital in Boston. It offers services in the areas of allergy and immunology, blood, cancer, circulatory, dermatology, digestive, heart, infectious diseases, kidneys, lung, obstetrics and gynecology, psychiatry, rheumatology, surgery, and urology; bones, muscles, and joints; brain, spine, and nervous system; endocrine, diabetes, and metabolism; and mouth, teeth, and face. The company also provides patient and family support services, such as billing and insurance, child care, emotional and support programs, executive health, international patient, medical interpreter, medical records, mind body medicine, nursing, nutrition, patient and ...
55 Fruit Street
Boston, MA 02114
Founded in 1811
Key Executives for The General Hospital Corporation
Chief of Dermatology Service, Director of Melanoma Program for Mgh Cancer Center and Director of Cutaneous Biology Research Center
Chairman of the Chiefs' Council
Chief of Medical Services and Physician-in-Chief
Compensation as of Fiscal Year 2015.
The General Hospital Corporation Key Developments
Massachusetts General Hospital Launches Phase II Trial of BCG Vaccine to Reverse Type 1 Diabetes FDA Approval of Trial Testing Generic Vaccine
Jun 7 15
Massachusetts General Hospital announced that phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Gurin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients, was announced at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory and principal investigator of the study. The five-year trial will investigate whether repeat BCG vaccination can clinically improve type 1 diabetes in adults between 18 and 60 years of age who have small but still detectable levels of insulin secretion from the pancreas. Faustmans research team was the first group to document reversal of advanced type 1 diabetes in mice and subsequently completed a successful phase I human clinical trial of BCG vaccination. She announced the FDA approval to launch the phase II trial during her ADA presentation, Low Levels of C-Peptide Have Clinical Significance for Established Type 1 Diabetes. A generic drug with over 90 years of clinical use and safety data, BCG is currently approved by the FDA for vaccination against tuberculosis and for the treatment of bladder cancer. The vaccine is known to elevate levels of the immune modulator tumor necrosis factor (TNF), which Faustmans team previously showed can temporarily eliminate in both humans and mice the abnormal white blood cells responsible for autoimmune type 1 diabetes. Increased TNF levels also stimulated production of protective regulatory T cells. In the phase I clinical trial, which was published in the August 8, 2012, issue of PLOS Medicine, two injections of BCG spaced four weeks apart led to temporary elimination of diabetes-causing T cells and provided evidence of a small, transient return of insulin secretion. The phase II clinical study will include more frequent dosing over a longer time period to determine the potential of repeat BCG vaccination to ameliorate the autoimmune state and improve clinical parameters such as HbA1c, a marker of average blood sugar control. In the new trial, which will be double blinded and conducted at MGH, 150 adults with long-term type 1 diabetes will be randomized to receive two injections four weeks apart of either BCG or placebo and then a single injection annually for the next four years. Patients will be closely monitored over the five-year trial period. The primary outcome measure will be improved results on the HbA1c blood test, which have been shown to prevent complications. More than $19 million has been raised out of a total of $25 million needed to conduct the phase II study over the next five years.
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12
May 18 15
OncoSec Medical Inc. announced it has entered a Sponsored Research Agreement (SRA) with Massachusetts General Hospital. Under the agreement, researchers will evaluate the immunologic mechanisms underlying the anti-tumor effects of OncoSec's clinical stage platform, ImmunoPulseTM IL-12, in a Human Papilloma Virus (HPV) tumor mouse model. HPV-associated tumors include oropharyngeal and certain genitourinary cancers (e.g., cervical cancer). OncoSec's immunotherapy platform, ImmunoPulseTM IL-12, is designed to deliver and enhance the uptake of DNA-based IL-12 directly into tumors. OncoSec is currently conducting Phase II clinical trials of ImmunoPulseTM IL-12 in metastatic melanoma and plans to initiate Phase II studies in head and neck cancer and triple negative breast cancer. Preliminary data from melanoma clinical trials show evidence that ImmunoPulseTM IL-12 can generate a local immune response as well as systemic anti-tumor effects. IL-12 is an inflammatory cytokine that regulates multiple aspects of the immune system and initiates both innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events that ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.
Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices
Dec 16 14
Infraredx, Inc. announced a collaboration with Massachusetts General Hospital (MGH) and coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS). The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.
Similar Private Companies By Industry
Recent Private Companies Transactions